PofoliaShared via Pofolia

Anesthesiology· 2015Q1· Clinical trial

Novel 10-kHz High-frequency Therapy (HF10 Therapy) Is Superior to Traditional Low-frequency Spinal Cord Stimulation for the Treatment of Chronic Back and Leg Pain

Leonardo Kapural, Cong Yu, Matthew W. Doust, Bradford E. Gliner et al.

Short summary

A new 10-kHz high-frequency spinal cord stimulation (HF10 therapy) significantly outperformed traditional low-frequency stimulation, achieving a 1.9x higher response rate for back pain and 1.5x for leg pain in a trial of 198 patients.

AI-generated from the title and abstract; the full text is not read.

Key points

  • HF10 therapy achieved an 84.5% back pain response rate vs. 43.8% for traditional SCS at 3 months.
  • Leg pain response rates were 83.1% for HF10 vs. 55.5% for traditional SCS.
  • The superiority of HF10 therapy was maintained through 12 months.
  • HF10 therapy did not cause paresthesias, a common side effect of traditional SCS.

AI-generated from the title and abstract; the full text is not read.

Abstract

AbstractAbstract This randomized trial involving 198 participants demonstrated that high-frequency spinal cord stimulation was superior to conventional spinal cord stimulation for the treatment of back pain and leg pain. The effects of high-frequency stimulation relative to conventional stimulation persisted for 12 months. Background: Current treatments for chronic pain have limited effectiveness and commonly known side effects. Given the prevalence and burden of intractable pain, additional therapeutic approaches are desired. Spinal cord stimulation (SCS) delivered at 10 kHz (as in HF10 therapy) may provide pain relief without the paresthesias typical of traditional low-frequency SCS. The objective of this randomized, parallel-arm, noninferiority study was to compare long-term safety and efficacy of SCS therapies in patients with back and leg pain. Methods: A total of 198 subjects with both back and leg pain were randomized in a 1:1 ratio to a treatment group across 10 comprehensive pain treatment centers. Of these, 171 passed a temporary trial and were implanted with an SCS system. Responders (the primary outcome) were defined as having 50% or greater back pain reduction with no stimulation-related neurological deficit. Results: At 3 months, 84.5% of implanted HF10 therapy subjects were responders for back pain and 83.1% for leg pain, and 43.8% of traditional SCS subjects were responders for back pain and 55.5% for leg pain ( P < 0.001 for both back and leg pain comparisons). The relative ratio for responders was 1.9 (95% CI, 1.4 to 2.5) for back pain and 1.5 (95% CI, 1.2 to 1.9) for leg pain. The superiority of HF10 therapy over traditional SCS for leg and back pain was sustained through 12 months ( P < 0.001). HF10 therapy subjects did not experience paresthesias. Conclusion: HF10 therapy promises to substantially impact the management of back and leg pain with broad applicability to patients, physicians, and payers.

The authors' abstract, as published at the source. Anesthesiology, 2015 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Anesthesiology and Pain Medicine

Anesthesiology and Pain MedicineMedicine